Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate, the active ingredient in Nesyrgy, is a calcium channel blocker presented as an oral tablet for oral use. It is combined with nebivolol hydrochloride, a beta‑blocker, to treat hypertension in adult patients requiring dual therapy.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured under EU GMP standards and distributed to regulated markets. Each batch undergoes rigorous testing to ensure potency, purity, and compliance with international regulatory requirements.

Nesyrgy, a combination antihypertensive, acts on vascular tone and cardiac output to lower blood pressure.

- Hypertension: reduces systolic and diastolic pressure in patients needing combined calcium‑channel blocker and beta‑blocker therapy. - Essential hypertension: improves overall blood pressure control when monotherapy is insufficient. - Isolated systolic hypertension: helps achieve target systolic values, especially in older adults.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Flushing: transient warmth and redness of the skin. - Fatigue: feeling of tiredness without exertion. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate that may cause fainting. - Heart block: impaired electrical conduction of the heart. - Angioedema: rapid swelling of face, lips, or throat. - Hepatic injury: abnormal liver function tests or jaundice. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Cardiac assessment: evaluate heart rate and conduction abnormalities. - Concomitant drugs review: check for other antihypertensives or agents affecting CYP3A4. - Hepatic function: adjust use in patients with moderate to severe liver impairment. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nesyrgy may interact with several medicines that affect blood pressure or drug metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels of both components. - Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive hypotensive effects. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increase risk of bradycardia and AV block.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance electrolyte disturbances and blood pressure reduction. - NSAIDs: can attenuate antihypertensive efficacy and affect renal function.